<DOC>
	<DOCNO>NCT01026090</DOCNO>
	<brief_summary>Primary Objective : To determine whether daily administration dronedarone start 5-7 day cardioversion superior dronedarone start cardioversion respect absence symptomatic , ECG confirm , atrial fibrillation ( AF ) recurrence 6 month adult patient persistent AF , cardioversion clinically indicate plan reduce symptom antiarrhythmic treatment clinically indicate reduce risk cardiovascular hospitalization due AF . Secondary Objectives : Main Secondary : - To assess number symptomatic AF recurrences/patient/6 month without ECG confirmation ; - To assess characteristic symptomatic AF recurrence two treatment arm ( frequency , duration episode , type , number , severity AF symptom per patient ) ; - To compare rate early recurrence AF two treatment strategy ; Other secondary : - To assess whether difference proportion patient symptomatic AF recurrence ( without ECG confirmation ) two treatment strategy ; - To assess whether difference number electrical cardioversions per patient two treatment strategy ; - To assess impact two strategy number shock , cumulative amount energy deliver , shock failure , immediate success cardioversion ; - To assess whether difference rate cardiovascular ( CV ) hospitalization length hospital stay two treatment strategy ; - To assess whether difference quality life two treatment strategy .</brief_summary>
	<brief_title>Dronedarone Pattern Use Patients Scheduled Elective Cardioversion ( ELECTRA )</brief_title>
	<detailed_description>The study period approximatively 6 month consist : - Double-blind treatment period ( placebo dronedarone ) 5-7 day prior cardioversion ; - Electrical cardioversion ; - Open-label treatment period dronedarone 6 month cardioversion .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Inclusion criterion : Adult patient persistent AF ( current episode screen visit &gt; 72 hr &lt; 12 month duration ) , cardioversion clinically indicate plan reduce symptom antiarrhythmic treatment clinically indicate reduce risk cardiovascular hospitalization due AF . Exclusion criterion : Severe congestive heart failure ( NYHA Class IV ) unstable hemodynamic condition ; Bradycardia &lt; 50 bpm ; QTc Bazett interval â‰¥500 m ; Second third degree atrioventricular ( AV ) block , sick sinus syndrome ( except use conjunction function pacemaker ) ; Severe hepatic impairment ; Pregnancy lactation ; History hypersensitivity reaction dronedarone excipients component container . Concomitant drug : Antiarrhythmic drug ( AADs ) dronedarone administer study withdrawn least five plasma halflives prior first study drug administration ; Dronedarone coadministered strong CYP3A4 inhibitor ; Dronedarone coadministered drug induce torsades de pointes . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>